Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age

NCT00343421 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT00343421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2006
Completion date
June 30, 2009
Enrollment
588 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, pertussis, poliomyelitis, tetanus